Search research articles
Contact Us
Filters
Showing results (31-40 of 72) with videos related to
Page
of 8
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
December 13, 2005
A study from the EORTC new drug development group: open label phase II study of sabarubicin (MEN-10755) in patients with progressive hormone refractory prostate cancer
W Fiedler, N Tchen, J Bloch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 19, 2011
Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients
J Cassidy, L Saltz, C Twelves, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 17, 1998
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer
M Mackean, A Planting, C Twelves, et al.
British Journal of Cancer
|
July 7, 2000
A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours
L C Pronk, P Vasey, A Sparreboom, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 8, 2011
Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy
C Twelves, W Scheithauer, J McKendrick, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 7, 2010
Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study
M Ranson, M Reck, A Anthoney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 1999
Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites
C Twelves, R Glynne-Jones, J Cassidy, et al.
British Journal of Cancer
|
February 20, 2014
Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial
E Chu, D Haller, T Cartwright, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 14, 1998
Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients
B Reigner, J Verweij, L Dirix, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 27, 2007
A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours
L Scott, O Soepenberg, J Verweij, et al.
Page
of 8
Search research articles
Search
Showing results (31-40 of 72) with videos related to
Sort By:
Page
of 8
European Journal of Cancer (Oxford, England : 1990)
|
December 13, 2005
A study from the EORTC new drug development group: open label phase II study of sabarubicin (MEN-10755) in patients with progressive hormone refractory prostate cancer
W Fiedler, N Tchen, J Bloch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 19, 2011
Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients
J Cassidy, L Saltz, C Twelves, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 17, 1998
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer
M Mackean, A Planting, C Twelves, et al.
British Journal of Cancer
|
July 7, 2000
A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours
L C Pronk, P Vasey, A Sparreboom, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 8, 2011
Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy
C Twelves, W Scheithauer, J McKendrick, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 7, 2010
Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study
M Ranson, M Reck, A Anthoney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 1999
Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites
C Twelves, R Glynne-Jones, J Cassidy, et al.
British Journal of Cancer
|
February 20, 2014
Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial
E Chu, D Haller, T Cartwright, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 14, 1998
Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients
B Reigner, J Verweij, L Dirix, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 27, 2007
A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours
L Scott, O Soepenberg, J Verweij, et al.
Page
of 8